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 1. SUPPLEMENTARY TABLES AND FIGURES 
1.1.   SUPPLEMENTARY TABLES 
Supplementary Table 1  Stage 1 results for the 14 SNPs that reached an association 
P value < 10-6 with body fat percentage in the stage 1 
genome-wide association meta-analysis and were taken 
forward for follow-up. 
Supplementary Table 2  Association of the 14 SNPs that were taken forward for 
replication from stage 1 with body fat percentage in a meta-
analysis of stage 2 follow-up studies. 
Supplementary Table 3  Association of the 14 SNPs that were taken forward for 
replication from stage 1 with body fat percentage in the 
combined meta-analysis of stage 1 and stage 2. 
Supplementary Table 4 Comparison of the combined stage 1 and stage 2 results for 
the rs2943650 SNP near IRS1, rs534870 SNP near SPRY2, 
and rs8050136 SNP in FTO in meta-analyses of ‘European 
individuals only’ vs. ‘Europeans and Indian-Asians combined’ 
Supplementary Table 5 Association of the body fat percentage decreasing (T) allele 
of rs2943650 near IRS1 with anthropometric traits in a 
meta-analysis of stage 2 follow-up studies. 
Supplementary Table 6 Association of the body fat percentage decreasing (T) allele 
of rs2943650 near IRS1 with blood lipids, insulin sensitivity 
traits, leptin, and adiponectin in a meta-analysis of stage 2 
and stage 3 follow-up studies. 
Supplementary Table 7 Significant associations (P < 0.05) of the rs2943650 SNP 
near IRS1 and the rs534870 SNP near SPRY2 with cis gene 
expression (cis-eQTLs) in subcutaneous adipose tissue, 
omental adipose tissue, blood, and liver. 
Supplementary Table 8 Association of the body fat percentage increasing (G) allele 
of rs534870 near SPRY2 with anthropometric traits and 
blood lipids in a meta-analysis of stage 2 follow-up studies. 
Supplementary Table 9 Association of established susceptibility loci for BMI, waist 
circumference, extreme obesity, and waist-to-hip ratio with 































1  GRIK3  rs12739617  36,945,244  G  C  35803  86  0.048  3.2x10‐5 28246  90  0.069  8.6x10‐7  19388  86  0.046  2.4x10‐3 16415  89  0.042  2.4x10‐2 
2  IRS1  rs2943650  226,814,165  C  T  36574  36  0.044  7.9x10‐9 29017  37  0.039  3.1x10‐6  19751  35  0.059  4.1x10‐8 16823  36  0.034  2.7x10‐3 
2  SNED1  rs7425888  241,575,678  A  G  33997  15  0.029  7.1x10‐3 26713  13  0.016  2.2x10‐1  18859  16  0.077  1.4x10‐7 15138  14  ‐0.027  1.1x10‐1 
5  HTR1A  rs7736910  63,076,529  G  A  32629  50  0.039  5.9x10‐7 27275  48  0.045  2.0x10‐7  16706  52  0.029  1.0x10‐2 15924  49  0.048  4.0x10‐5 
5  MARCH3  rs7738021  126,230,059  G  T  32629  68  0.033  1.9x10‐4 27275  71  0.036  2.6x10‐4  16706  66  0.009  4.5x10‐1 15924  69  0.065  9.9x10‐7 
6  WISP3  rs6909893  112,466,236  A  G  34831  26  0.045  7.6x10‐7 27274  28  0.043  9.9x10‐6  18908  25  0.059  6.5x10‐6 15923  27  0.028  3.6x10‐2 
8  PPP1R3B  rs17706711  9,116,692  A  T  29050  81  0.060  1.5x10‐7 27274  81  0.060  1.5x10‐7  13240  82  0.070  9.4x10‐5 15811  82  0.051  1.4x10‐3 
8  RP1L1  rs9657518  10,504,999  C  T  34558  39  0.038  1.9x10‐5 27274  34  0.050  7.4x10‐7  18635  41  0.035  3.4x10‐3 15923  35  0.036  8.3x10‐3 
8  FDFT1  rs17149412  11,719,247  C  T  32628  28  0.044  8.8x10‐7 27274  27  0.054  7.5x10‐8  16705  29  0.032  1.1x10‐2 15923  27  0.054  6.3x10‐5 
8  SLC39A14  rs12674913  22,319,562  G  C  36612  69  0.043  1.6x10‐7 29055  72  0.035  1.4x10‐4  19777  68  0.046  4.0x10‐5 16835  71  0.043  6.0x10‐4 
10  GFRA1  rs180585  117,797,907  C  T  36603  84  0.049  7.9x10‐7 29046  84  0.054  1.1x10‐6  19726  84  0.026  6.5x10‐2 16830  84  0.074  6.7x10‐7 
13  SPRY2  rs534870  79,857,208  G  A  36488  33  0.036  3.2x10‐6 28931  31  0.044  7.9x10‐7  19726  35  0.034  1.6x10‐3 16763  32  0.039  9.0x10‐4 
16  FTO  rs8050136  52,373,776  A  C  36537  39  0.063  3.9x10‐17 28980  41  0.067  4.6x10‐16  19739  38  0.058  2.5x10‐8 16798  40  0.063  1.2x10‐8 

































  34,254  88  0.015  1.8x10‐1   20,490  88  0.009  5.2x10‐1
 
13,764  89  0.026  1.7x10‐1 




  39,576  36  0.025  1.9x10‐4   24,047  36  0.035  3.4x10‐5   15,529  36  0.008  4.7x10‐1 
2  SNED1  rs7425888  241,575,678  A  G  rs4521036  1 
 








  34,392  14  0.021  4.1x10‐2   20,562  13  0.016  2.3x10‐1   13,830  14  0.029  7.9x10‐2 
5  HTR1A  rs7736910  63,076,529  G  A  rs10805383  1   24,407  55  0.015  7.9x10‐2   15,506  57  0.010  1.6x10‐1   8,901  50  0.015  2.9x10‐1 
5  MARCH3  rs7738021  126,230,059  G  T    24,437  64 ‐0.003  7.5x10‐1   15,543  62  0.004  6.8x10‐1   8,894  67 ‐0.018  2.4x10‐1 
6  WISP3  rs6909893  112,466,236  A  G  rs2280153  0.85 34,428  26  0.022  6.9x10‐3   20,555  24  0.023  3.1x10‐2   13,873  28  0.021  1.0x10‐1 
8  PPP1R3B  rs17706711  9,116,692  A  T  rs2929313  1   34,403  83 ‐0.003  7.6x10‐1   20,550  84  0.001  9.2x10‐1   13,853  82 ‐0.009  5.5x10‐1 
8  R1P1L1  rs9657518  10,504,999  C  T    34,556  45  0.004  6.3x10‐1   20,632  49  0.006  5.0x10‐1   13,924  62 ‐0.001  9.4x10‐1 
8  FDFT1  rs17149412  11,719,247  C  T    24,435  33 ‐0.005  5.7x10‐1   15,534  34 ‐0.005  6.7x10‐1   8,901  27 ‐0.017  2.9x10‐1 




  31,715  71  0.013  9.9x10‐2   17,804  70  0.017  1.1x10‐1   13,911  72  0.008  5.2x10‐1 
10  GFRA1  rs180585  117,797,907  C  T  rs180566  1   34,405  84  0.012  2.2x10‐1   20,574  83  0.010  4.3x10‐1   13,831  84  0.015  3.3x10‐1 
13  SPRY2  rs534870  79,857,208  G  A    34,342  30  0.023  2.6x10‐3   20,537  30  0.030  2.1x10‐3   13,805  30  0.012  3.4x10‐1 




  34,105  40  0.047  4.4x10‐11   20,624  41  0.045  6.0x10‐7   13,481  40  0.051  1.6x10‐5 

































1  GRIK3  rs12739617  36,945,244  G  C  70,057  87  0.031  1.2x10‐4 62,500  89  0.036  4.2x10‐5  39,878  86  0.025  1.3x10‐3 30,179  89  0.034  1.0x10‐2 
2  IRS1  rs2943650  226,814,165  C  T  76,150  36  0.034  3.8x10‐11 68,593  36  0.031  6.0x10‐9  43,798  36  0.044  2.9x10‐11 32,352  36  0.021  9.0x10‐3 
2  SNED1  rs7425888  241,575,678  A  G  68,389  14  0.025  8.9x10‐4 61,105  13  0.019  1.9x10‐2  39,421  15  0.044  9.3x10‐6 28,968  14  0.002  8.8x10‐1 
5  HTR1A  rs7736910  63,076,529  G  A  57,036  52  0.028  1.5x10‐6 51,682  51  0.030  1.2x10‐6  32,212  55  0.021  6.0x10‐3 24,825  50  0.034  1.2x10‐4 
5  MARCH3  rs7738021  126,230,059  G  T  57,066  66  0.015  1.7x10‐2 51,712  67  0.014  3.2x10‐2  32,249  64  0.006  4.2x10‐1 24,818  68  0.030  3.2x10‐3 
6  WISP3  rs6909893  112,466,236  A  G  69,259  26  0.033  8.7x10‐8 61,702  27  0.031  9.5x10‐7  39,463  24  0.038  5.5x10‐6 29,796  28  0.024  8.4x10‐3 
8  PPP1R3B  rs17706711  9,116,692  A  T  63,453  82  0.023  1.6x10‐3 61,677  82  0.023  1.6x10‐3  33,790  83  0.024  2.1x10‐2 29,664  82  0.019  7.9x10‐2 
8  R1P1L1  rs9657518  10,504,999  C  T  69,114  42  0.018  1.9x10‐3 61,830  41  0.019  1.1x10‐3  39,267  46  0.017  2.1x10‐2 29,847  37  0.016  8.5x10‐2 
8  FDFT1  rs17149412  11,719,247  C  T  57,063  30  0.018  5.3x10‐3 51,709  30  0.019  4.2x10‐3  32,239  32  0.011  1.8x10‐1 24,824  27  0.025  1.7x10‐2 
8  SLC39A14  rs12674913  22,319,562  G  C  68,327  70  0.028  1.1x10‐6 60,770  71  0.023  1.7x10‐4  37,581  69  0.030  6.5x10‐5 30,746  72  0.026  3.5x10‐3 
10  GFRA1  rs180585  117,797,907  C  T  71,008  84  0.030  1.6x10‐5 63,451  84  0.030  3.7x10‐5  40,300  84  0.017  7.0x10‐2 30,661  84  0.046  2.0x10‐5 
13  SPRY2  rs534870  79,857,208  G  A  70,831  32  0.030  6.5x10‐8 63,273  30  0.032  3.2x10‐8  40,263  32  0.032  1.1x10‐5 30,568  31  0.026  2.2x10‐3 
16  FTO  rs8050136  52,373,776  A  C  70,642  40  0.055  2.7x10‐26 63,085  41  0.056  5.6x10‐25  40,363  40  0.051  1.3x10‐13 30,279  40  0.058  1.1x10‐12 







Locus  Meta‐analysis  N  Freq (%) beta  P  I2 
All, European + Indian Asian  76,150  64  ‐0.034  3.8x10‐11  22% 
All, European  68,593  64  ‐0.031  6.0x10‐9  21% 
All, Indian Asian  7,557  71  ‐0.065  2.7x10‐4  0% 
Men, European + Indian Asian  43,798  64  ‐0.044  2.9x10‐11  22% 
Men, European  37,263  64  ‐0.042  5.8x10‐9  21% 




Women, European  31,330  64  ‐0.018  0.030  1% 
All, European + Indian Asian  70,831  68  ‐0.030  6.5x10‐8  14% 
All, European  63,273  70  ‐0.032  3.2x10‐8  15% 
All, Indian Asian  7,557  58  ‐0.011  0.52  0% 
Men, European + Indian Asian  40,263  68  ‐0.032  1.1x10‐5  23% 
Men, European  33,727  70  ‐0.041  3.6x10‐7  23% 




Women, European  29,546  69  ‐0.024  0.0064  0% 
All, European + Indian Asian  70,642  60  ‐0.055  2.7x10‐26  17% 
All, European  63,085  59  ‐0.056  5.6x10‐25  17% 
All, Indian Asian  7,557  68  ‐0.044  0.012  0% 
Men, European + Indian Asian  40,363  60  ‐0.051  1.3x10‐13  29% 
Men, European  33,828  59  ‐0.050  1.9x10‐11  29% 




Women, European  29,257  60  ‐0.057  2.9x10‐12  9% 










All individuals  Men  Women   
Trait  n  beta (se)  P  n  beta (se)  P  n  beta (se)  P  Pdiff 
BMI , kg/m  43,291 ‐0.026 (0.026) 0.32 24,731 ‐0.046 (0.032)  0.16 18,560 0.012 (0.045) 0.79 0.30
Height, m  43,205 ‐0.018 (0.044) 0.68 24,692 0.014 (0.060)  0.82 18,513 ‐0.055 (0.064) 0.39 0.43
Weight, kg  43,208 ‐0.076 (0.085) 0.37 24,688 ‐0.156 (0.113)  0.17 18,520 0.029 (0.129) 0.82 0.28
Waist circumference, cm 21,850 0.063 (0.098) 0.52 10,609 0.062 (0.134)  0.65 11,241 0.065 (0.143) 0.65 0.99
Hip circumference, cm 21,834 ‐0.040 (0.072) 0.58 10,604 ‐0.026 (0.088)  0.76 11,230 ‐0.068 (0.128) 0.59 0.77
Waist‐to‐hip ratio 21,832 0.0009 (0.0006) 0.13 10,602 0.0007 (0.0008)  0.40 11,230 0.0011 (0.0008) 0.19 0.72
  n  OR (95% CI)  P  n  OR (95% CI)  P  n  OR (95% CI)  P  Pdiff 
Obesity (BMI ≥30 vs. BMI <25) 26,009 0.98 (0.94‐1.02) 0.36 13,518 0.94 (0.89‐1.00)  0.044 12,491 1.03 (0.96‐1.10) 0.40 0.048
Overweight (BMI ≥25 vs. BMI <25) 
 








All individuals  Men  Women   
Trait  n  beta (se)  P  n  beta (se)  P  n  beta (se)  P  Pdiff 
HDL cholesterol  20,596   ‐0.054 (0.010) 1.0x10‐7 9,937 ‐0.077 (0.015) 1.7x10‐7 10,659 ‐0.033 (0.014) 0.019 0.027
LDL cholesterol  20,596  0.020 (0.010) 0.045 9,937 0.031 (0.015) 0.033 10,659  0.010 (0.013) 0.44 0.26
Triglycerides  21,168  0.042 (0.010) 2.0x10‐5 10,320 0.066 (0.014) 5.8x10‐6 10,848  0.022 (0.013) 0.11 0.025





‐0.032 (0.031)  0.30  1,410 ‐0.035 (0.037)  0.34  543 ‐0.025 (0.058)  0.67  0.88 
Ins‐AUC / Glu‐AUC  9,572  0.047 (0.015)  0.0014  8,376  0.051 (0.016)  0.0011  1,196  0.017 (0.042)  0.69  0.45 
Matsuda index  13,520 ‐0.036 (0.012)  0.0043  11,333 ‐0.035 (0.014)  0.010  2,187 ‐0.037 (0.030)  0.22  0.95 
Gutt index  13,815 ‐0.033 (0.012)  0.0083  11,472 ‐0.033 (0.014)  0.015  2,343 ‐0.029 (0.028)  0.31  0.89 
Leptin a  4,641 ‐0.027 (0.021)  0.21  3,530 ‐0.027 (0.024)  0.26  1,111 ‐0.026 (0.044)  0.55  0.98 














 Supplementary Table 7    Significant  associations  (P < 0.05)* of  the  rs2943650  SNP near  IRS1  and  the  rs534870  SNP near 
SPRY2 with cis gene expression  (cis‐eQTLs)  in subcutaneous adipose  tissue, omental adipose  tissue, blood,  liver, and brain 
from three populationsa, b, c 
SNP  Tissue  Sample  Gene  n  Effect d  P*  Padj
e  Peak SNP f  r2 g  P  Padj
h 
All individuals                       
rs2943650  Subcutaneous fat  Surgery patientsa  IRS1  590  ‐  4.2x10‐4  0.93  rs2943653  0.81  6.3x10‐6 0.37 
      BC018684  607  +  0.0017  NA  NA  NA  NA  NA 
      Contig24493_RC  605  ‐  4.9x10‐4 0.98  rs2943653  0.81  5.3x10‐5 0.64 
      Contig50189_RC  600  ‐  0.0098  NA  NA  NA  NA  NA 
      ENST00000272907  609  +  0.032  NA  NA  NA  NA  NA 
  Subcutaneous fat  General populationb  IRS1  604  ‐  9.6x10‐10 0.63  rs2176040  1.00  9.6x10‐10 0.62 
      Contig 50189_RC  604  ‐  7.1x10‐5  0.72  rs2943653  0.79  3.7x10‐5 0.25 
  Omental fat  Surgery patientsa  IRS1  714  ‐  2.3x10‐8 0.97  rs908252  0.89  3.0x10‐9 0.74 
      Contig24493_RC  738  ‐  2.6x10‐4 0.85  rs10933137  0.66  5.9x10‐5 0.51 
      Contig39389_RC  739  ‐  0.024  NA  NA  NA  NA  NA 
      Contig50189_RC  735  ‐  0.013  0.0087  rs3769647  0.00  1.6x10‐5 1.1x10‐5 
      ENST00000272907  740  ‐  0.0080  NA  NA  NA  NA  NA 
  Blood  General populationb  COL4A4  745  ‐  0.03  0.16  rs13398103  0.00  5.4x10‐30 3.2 x10‐29
rs534870  Blood  General populationb  SPRY2  745  ‐  3.7x10‐4 7.9x10‐4  rs7995973  0.00  4.2x10‐14 9.1x10‐14
Men                     
rs2943650  Subcutaneous fat  Surgery patientsa  IRS1  171  ‐  0.017  0.52  rs2943653  0.82  5.7x10‐5 0.20 
      Contig24493_RC  175  ‐  0.010  0.49  rs2943653  0.82  0.0012  0.37 
      Contig50189_RC  174  ‐  0.0095  NA  NA  NA  NA  NA 
  Subcutaneous fat  General populationb  IRS1  252  ‐  2.2x10‐8 0.61  rs2943645  0.97  2.1x10‐8 0.59 
      Contig 50189_RC  252  ‐  0.0091  0.0084  rs11694119  0.01  2.9x10‐4 2.7x10‐4 
  Omental fat  Surgery patientsa  IRS1  188  ‐  9.7x10‐4 0.92  rs908252  0.85  4.5x10‐5 0.60 
      COL4A4  192  ‐  0.014  0.066  rs6706802  0.02  3.5x10‐6 2.1x10‐5 
      Contig39389_RC  192  ‐  0.0070  NA  NA  NA  NA  NA 
rs534870  Omental fat  Surgery patientsa  HSS00006179  193  +  8.6x10‐4 NA  NA  NA  NA  NA 
      XM_090673  192  +  0.035  NA  NA  NA  NA  NA 
  Blood  General populationb  ARF4  312  ‐  0.022  0.031  rs12583018  0.01  0.002  0.0028 
Women                     
rs2943650  Subcutaneous fat  Surgery patientsa  IRS1  416  ‐  0.017  0.91  rs2943653  0.80  0.011  0.73 
      BC018684  430  +  0.011  NA  NA  NA  NA  NA 
      Contig24493_RC  427  ‐  0.015  0.89  rs2943653  0.80  0.0088  0.76 
  Subcutaneous fat  General populationb  IRS1  352  ‐  2.7x10‐4 0.0010  rs1190117  0.01  1.1x10‐4 4.4x10‐4 
      Contig50189_RC  352  ‐  0.0019  0.88  rs2138157  0.89  0.0019  0.87 
  Omental fat  Surgery patientsa  Contig24493_RC  543  +  0.0024  0.73  rs10933137  0.69  7.3x10‐4 0.57 
      Contig50189_RC  539  ‐  0.037  0.45  rs3769647  0.00  3.0x10‐4 3.7x10‐4 
      ENST00000272907  545  ‐  0.0094  NA  NA  NA  NA  NA 
  Liver  Surgery patientsa  HSS00339567  405  +  0.045  NA  NA  NA  NA  NA 
   Blood  General populationb  SPRY2  433  ‐  0.0012  0.0083  rs518627  0.01  1.0x10‐9 7.3x10‐9 
The  gene  transcripts  that  were  tested  for  rs2943650  were  BC014369,  BC018685,  BC035052,  Contig24493_RC,  Contig39389_RC,  Contig50189_RC, 
ENST00000272907,  hCT1970673,  HSS00207461,  HSS00339567,  COL4A3  (NM_000091  and  NM_031362),  COL4A4  (NM_000092),  IRS1  (NM_005544),  and 
RHBDD1 (NM_032276).  




for  a  statistically  significant  association  with  Bonferroni  correction  is  P=0.0019;  a  Tissue  samples  from  patients  who  underwent  bariatric  surgery  (see 
Supplementary Note ‐ Methods); b Tissue samples from general population (see Supplementary Note ‐ Methods); c Neutopathologically normal cortical brain 








All individuals  Men    Women   
Trait  n  beta (se)  P  n  beta (se)  P  n  beta (se)  P  Pdiff 








‐0.034 (0.046) 0.46 24,656 0.083 (0.062)  0.18 18,391 ‐0.169 (0.067) 0.012 0.0060
Weight, kg  43,049 ‐0.284 (0.089) 0.0014 24,652 ‐0.138 (0.118)  0.24 18,397 ‐0.473 (0.134) 0.043 0.060
Waist circumference, cm 21,607 ‐0.119 (0.102) 0.24 10,516 ‐0.078 (0.139)  0.57 11,091 ‐0.167 (0.150) 0.26 0.66
Hip circumference, cm 21,591 ‐0.070 (0.074) 0.35 10,510 0.025 (0.092)  0.78 11,081 ‐0.259 (0.129) 0.045 0.031
Waist‐to‐hip ratio 20,431 ‐0.0003 (0.0006) 0.62 10,602 ‐0.0011 (0.0009)  0.20 9,829 0.0005 (0.0009) 0.55 0.18
HDL cholesterol 20,351  0.010 (0.011) 0.36 9,847 ‐0.006 (0.015)  0.69 10,504 0.025 (0.015) 0.10 0.15
LDL cholesterol  20,351  0.005 (0.010) 0.62 9,847 0.000 (0.015)  0.99 10,504 0.009 (0.014) 0.50 0.65
Triglycerides  20,897 ‐0.014 (0.010) 0.16 10,311 ‐0.000 (0.015)  0.97 10,803 ‐0.026 (0.014) 0.060 0.21
M/I‐ratio  1,974  0.052 (0.034) 0.13 1,410 0.069 (0.041)  0.094 564 0.015 (0.060) 0.81 0.46
Ins‐AUC / Glu‐AUC  9,454 ‐0.010 (0.016) 0.54 8,308 ‐0.000 (0.017)  0.98 1,146 ‐0.072 (0.044) 0.10 0.13
Matsuda index  11,379  0.013 (0.014) 0.33 9,777 0.003 (0.015)  0.82 1,612 0.100 (0.037) 0.0062 0.014
Gutt index  11,569  0.032 (0.014) 0.032 9,917 0.021 (0.015)  0.18 1,754 0.089 (0.035) 0.011 0.072
 
n  OR (95% CI)  P  n  OR (95% CI)  P  n  OR (95% CI)  P  Pdiff 
Obesity (BMI ≥30 vs. BMI <25) 25,940  0.93 (0.89‐0.97) 0.0010 13,521 0.92 (0.87‐0.98)  0.0095 12,419 0.93 (0.87‐1.00) 0.041 0.79
Overweight (BMI ≥25 vs. BMI <25) 
 
























1  TNNI3K  rs1514175  A  G  36,563  44  0.009  2.4x10‐1  BMI  8 
1  PTBP2  rs10489741  A  G  36,568  57  0.020  7.8x10‐3  BMI  8 
1  NEGR1  rs2815752  A  G  36,602  62  0.022  4.3x10‐3  BMI  6,7 
1  SEC16B  rs10913469  C  T  36,580  19  0.030  1.5x10‐3  BMI  6 
2  LRP1B  rs2890652  C  T  29,035  18  0.001  9.4x10‐1  BMI  8 
2  FANCL  rs887912  T  C  29,049  29  0.019  3.4x10‐2  BMI  8 
2  RBJ  rs713586  C  T  36,542  47  0.015  4.7x10‐2  BMI  8 
2  TMEM18  rs7561317  G  A  36,351  66  0.032  9.3x10‐4  BMI  6,7 
3  CADM2  rs13078807  G  A  27,275  20  0.018  7.8x10‐2  BMI  8 
3  ETV5  rs7647305  C  T  36,546  79  0.013  1.5x10‐1  BMI  6 
4  SLC39A8  rs13107325  T  C  27,275  8  0.027  1.2x10‐1  BMI  8 
4  GNPDA2  rs10938397  G  A  36,610  43  0.026  1.2x10‐3  BMI  7 
5  ZNF608  rs4836133  A  C  27,274  47  0.032  2.4x10‐4  BMI  8 
5  FLJ35779  rs2112347  T  G  36,600  59  0.003  6.9x10‐1  BMI  8 
6  NUDT3  rs206936  G  A  36,620  24  0.010  2.7x10‐1  BMI  8 
6  TFAP2B  rs987237  G  A  36,614  18  0.025  8.2x10‐3  BMI  8 
9  LRRN6C  rs10968576  G  A  36,618  29  0.015  7.4x10‐2  BMI  8 
11  RPL27A  rs4929949  C  T  32,629  50  0.007  3.7x10‐1  BMI  8 
11  MTCH2  rs10838738  G  A  36,587  34  0.017  3.0x10‐2  BMI  7 
11  BDNF  rs4923461  A  G  36,599  77  0.023  6.4x10‐3  BMI  6 
12  FAIM2  rs7138803  A  G  36,572  37  0.025  1.0x10‐3  BMI  6 
13  MTIF3  rs4771122  G  A  34,832  22  0.011  2.3x10‐1  BMI  8 
14  PRKD1  rs11847697  T  C  27,872  5  0.061  5.2x10‐3  BMI  8 
14  NRXN3  rs10146997  G  A  29,012  20  0.003  8.1x10‐1  BMI  8 
15  MAP2K5  rs2241423  G  A  29,064  78  0.013  2.0x10‐1  BMI  8 
16  GPRC5B  rs12444979  C  T  29,021  87  0.016  2.0x10‐1  BMI  8 
16  SH2B1  rs7498665  G  A  36,598  36  0.029  2.3x10‐4  BMI  6,7 
16  FTO  rs8050136  A  C  36,537  39  0.063  3.9x10‐17  BMI  3,5 
18  MC4R  rs17782313  C  T  35,798  28  0.039  2.1x10‐6  BMI  4 
19  TMEM160  rs3810291  A  G  34,832  62  0.001  9.4x10‐1  BMI  8 
19  QPCTL  rs2287019  C  T  22,188  82  0.036  5.0x10‐3  BMI  8 
19  KCTD15  rs29941  G  A  34,408  66  0.013  1.0x10‐1  BMI  6,7 
6  TFAP2B  rs987237  G  A  36,613  18  0.025  8.2x10‐3  Waist  26 
8  MSRA  rs7826222  G  C  18,566  23  0.012  3.8x10‐1  Waist  26 
14  NRXN3  rs10146997  G  A  29012  20  0.003  8.1x10‐1  Waist  25 
1  SDCCAG8  rs12145833  T  G  36,342  84  0.014  1.7x10‐1  Extreme obesity  28 
8  TNKS/MSRA  rs473034  T  C  34,832  11  0.012  4.5x10‐2  Extreme obesity  28 
10  PTER  rs10508503  C  T  26,034  91  0.018  3.1x10‐1  Extreme obesity  27 
16  MAF  rs1424233  T  C  36,309  52  0.005  4.8x10‐1  Extreme obesity  27 
18  NPC1  rs1805081  T  C  33,460  60  0.016  4.5x10‐2  Extreme obesity  27 
1  TBX15  rs984222  G  C  36,596  58  ‐0.006  4.2x10‐1  WHR adj BMI  29 
1  LYPLAL1  rs4846567  G  T  36,591  73  ‐0.024  4.4x10‐3  WHR adj BMI  26,29 
1  DNM3  rs1011731  G  A  36,522  43  ‐0.005  5.1x10‐1  WHR adj BMI  29 
2  GRB14  rs10195252  T  C  34,832  60  ‐0.025  1.3x10‐3  WHR adj BMI  29 
3  ADAMTS9  rs6795735  C  T  36,603  51  ‐0.011  1.4x10‐1  WHR adj BMI  29 
3  NISCH  rs6784615  T  C  34,291  94  0.003  8.5x10‐1  WHR adj BMI  29 
5  CPEB4  rs6861681  A  G  32,628  29  ‐0.012  1.8x10‐1  WHR adj BMI  29 
6  RSPO3  rs9491696  G  C  36,564  49  ‐0.009  2.1x10‐1  WHR adj BMI  29 
6  VEGFA  rs6905288  A  G  36,332  59  0.000  9.8x10‐1  WHR adj BMI  29 
6  LY86  rs1294421  G  T  36,604  58  ‐0.005  5.5x10‐1  WHR adj BMI  29 
7  NFE2L3  rs1055144  T  C  36,548  24  ‐0.013  1.4x10‐1  WHR adj BMI  29 
12  ITPR2  rs718314  G  A  36,339  24  ‐0.011  2.0x10‐1  WHR adj BMI  29 
12  HOXC13  rs1443512  A  C  35,670  25  0.006  5.1x10‐1  WHR adj BMi  29 





 1.2.   SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1  Study design and participating cohorts. 
Supplementary Figure 2  Manhattan plots showing the significance of association with 
body fat percentage for all SNPs in the stage 1 meta-
analysis in all individuals (n=36,626), individuals of 
European descent (n=29,069), men (n=19,815), and 
women (n=16,811).  
Supplementary Figure 3  Association of the rs2943650 SNP (near-IRS1) body fat 
percentage decreasing (T) allele with body fat percentage 
and insulin sensitivity (measured with the Matsuda index) 
among 6,489 men from the METSIM (Metabolic Syndrome in 
Men) study with and without adjustment of each trait with 
the other. 
Supplementary Figure 4 Association of SNPs within ±1 Mb from the rs2943650 SNP 
and ±1 Mb from the rs534870 SNP with the expression of 
IRS1 and SPRY2, respectively, in omental and subcutaneous 
adipose tissue. 
Supplementary Figure 5 Expression of the IRS1 gene in isolated adipocytes from 
visceral and subcutaneous adipose tissues of male and 
female mice. 
Supplementary Figure 6 Expression of the IRS1 gene in visceral and subcutaneous 
adipose tissues of men and women. 
Supplementary Figure 7  Quantile-quantile plots and genomic control parameters (λ) 
for the association with body fat percentage in all individuals 
(n=36,626), individuals of European descent (n=29,069), 






Supplementary Figure 1  Study design and participating cohorts. Stage 1 - Meta-analysis of 
genome-wide association data was performed in stage 1 across 15 studies of white European 
ancestry and a total of 14 SNPs representing the best associating (P < 10-6) loci were taken 
forward for replication. Stage 2 – The 14 SNPs were genotyped in 11 studies of adults of European 
ancestry, and tested for association with body fat percentage, as well as with BMI, height, weight, 
risk of obesity, and risk of overweight. Stage 3 - Additional follow-up analyses were performed for 





Supplementary Figure 2  Manhattan plots showing the significance of association with body fat 
percentage for all SNPs in the stage 1 meta-analysis in all individuals (n=36,626), individuals of 
European descent (n=29,069), men (n=19,815), and women (n=16,811). The –log10P values for 
the association of each single nucleotide polymorphism with BMI are shown on the y-axis. SNPs 
are plotted on the x-axis according to their position on each chromosome against association with 
body fat percentage on the y-axis (shown as –log10 P-value). The loci coloured in red reached a P 





Supplementary Figure 3  Association of the rs2943650 SNP (near-IRS1) body fat percentage 
decreasing (T) allele with body fat percentage and insulin sensitivity (measured with the Matsuda 
index) among 6,489 men from the METSIM (Metabolic Syndrome in Men) study with and without 
adjustment of each trait with the other. Beta, change in phenotype per each body fat percentage 




Supplementary Figure 4  Association of SNPs within ±1 Mb from the rs2943650 SNP and ±1 Mb 
from the rs534870 SNP with the expression of IRS1 and SPRY2, respectively, in omental and 
subcutaneous adipose tissue from patients who underwent bariatric surgery (see 




























Supplementary Figure 5  Expression of the IRS1 gene in isolated adipocytes from visceral and 
subcutaneous adipose tissues of male and female mice. VISC, adipocytes from visceral adipose 
tissue. SUBQ, adipocytes from subcutaneous adipose tissue. *A statistically significant (P<0.05) 

































P =0.021 P =0.52
 
Supplementary Figure 6  Expression of the IRS1 gene in visceral and subcutaneous 
adipose tissues of men and women. P values indicate the difference in IRS1 expression 
between men and women. The analyses on visceral fat included 26 men and 75 women 






Supplementary Figure 7  Quantile-quantile plots and genomic control parameters (λ) for the 
association with body fat percentage in all individuals (n=36,626), individuals of European descent 
(n=29,069), men (n=19,815), and women (n=16,811). The plots shown were corrected for 





 2. SUPPLEMENTARY NOTE 
 
2.1. SUPPLEMENTARY NOTE - TABLES 
 
Supplementary Note - Table 1  Number of individuals and sample quality control for 
genome-wide association studies of stage 1. 
Supplementary Note - Table 2  Information on genotyping methods, quality control 
of SNPs, imputation, and statistical analysis for 
genome-wide association studies of stage 1. 
Supplementary Note - Table 3  Study-specific descriptive statistics for genome-wide 
association studies of stage 1. 
Supplementary Note - Table 4  Number of individuals and sample quality control for 
stage 2 and stage 3 follow-up studies with de novo 
genotyping. 
Supplementary Note - Table 5  Information on genotyping methods, quality control 
of SNPs, and association analysis software for stage 
2 and stage 3 follow-up studies with de novo 
genotyping. 
Supplementary Note - Table 6  Number of individuals and sample quality control for 
stage 2 and stage 3 follow-up studies with in silico 
genotyping. 
Supplementary Note - Table 7  Information on genotyping methods, quality control 
of SNPs, imputation, and association analysis 
software for stage 2 and stage 3 follow-up studies 
with in silico genotyping. 
Supplementary Note - Table 8  Study-specific descriptive statistics for stage 2 and 
stage 3 follow-up studies. 
Supplementary Note - Table 9  Samples and assays used for the measurement of 
circulating levels of glucose, insulin, leptin, and 


















Amish The Old Order Amish 1,186 ≥ 96% 1) failed Mendelian check
2) failed duplicate check
3) missing body fat percentage data



















CoLaus Cohort Lausannoise 6,188 ≥ 90% 1) ethnic outliers
2) related individuals and duplicates
3) missing body fat percentage data
























ERF Erasmus Rucphen Family 2,315 > 95% 1) gender mismatch
2) ethnic outliers
3) missing body fat percentage data






















































Framingham Framingham Heart Study 3,780 ≥ 97% 1) autosomal heterozygosity <0.33 or >0.37
2) ethnic outliers (using Eigenstrata)
3) missing body fat percentage data























































































p for HWE All Men Women
AGES Illumina 370K BeadStudio > 10‐6 315,410 MACH r2‐hat ≥ 0.30 2,465,997 ‐ 1.020 1.029 ProbABEL
Amish Affymetrix 500K BRLMM > 10‐6 382,935 MACH r2‐hat ≥ 0.30 2,302,463 1.049 1.018 1.077 ITSNBN
CHS Illumina 370‐CNV BeadStudio > 10‐5 306,655 BimBam
observed/expected 
variance  ≥ 0.30
2,195,299 ‐ 1.014 1.020 R
CoLaus Affymetrix 500K BRLMM > 10‐7 390,631 IMPUTE proper‐info ≥ 0.40 2,439,888 ‐ 1.020 1.022 QUICKTEST
EPIC‐Obesity (obese cases) Affymetrix 500K BRLMM > 10‐6 397,438 IMPUTE proper‐info ≥ 0.40 2,381,011 ‐ 1.170 0.994 SNPtest




BeadStudio, BRLMM >10‐6 487,573 MACH r2‐hat ≥ 0.30 2,468,052 1.017 1.001 1.017 ProbABEL
FamHS Illumina 1 Million BeadStudio > 10‐6 874,830 MACH r2‐hat ≥ 0.30 2,375,698 1.031 1.035 1.043 SAS




BRLMM > 10‐6 378,163 MACH r2‐hat ≥ 0.30 2,455,944 0.991 1.020 1.012 R
GOOD Illumina 610K BeadStudio > 10‐6 521,160 MACH r2‐hat ≥ 0.30 2,503,211 ‐ 1.015 ‐ MACH2QTL
KORAS3 Affymetrix 500K BRLMM ‐ 490,032 MACH r2‐hat ≥ 0.30 2,416,530 ‐ 1.002 1.010 MACH2QTL
KORAS4/F4 Affymetrix 6.0 Birdseed2 ‐ 909,622 IMPUTE proper‐info ≥ 0.40 2,040,316 ‐ 1.023 0.993 SNPtest
LOLIPOP Affymetrix 500K (Caucasians) BRLMM > 10‐6 374,773 MACH r2‐hat ≥ 0.30 2,444,407 ‐ 1.018 0.989 MACH2QTL
LOLIPOP Illumina 317K (Indian‐Asians) Beadstudio > 10‐6 245,892 MACH r2‐hat ≥ 0.30 1,896,366 ‐ 1.003 ‐ MACH2QTL
LOLIPOP Illumina 610K (Indian‐Asians) Beadstudio > 10‐6 544,390 MACH r2‐hat ≥ 0.30 2,147,795 ‐ 1.027 1.014 MACH2QTL
LOLIPOP Perlegen (Caucasians) Custom > 10‐6 202,544 MACH r2‐hat ≥ 0.30 2,398,436 ‐ 1.007 ‐ MACH2QTL
LOLIPOP Perlegen (Indian‐Asians) Custom > 10‐6 170,055 MACH r2‐hat ≥ 0.30 1,546,962 ‐ 0.979 ‐ MACH2QTL
Rotterdam Illumina Infinium 550 BeadStudio > 10‐6 512,349 MACH r2‐hat ≥ 0.30 2,488,215 ‐ 1.010 1.019 MACH2QTL









































N Age, yrs BMI, kg/m² Height, m Weight, kg
Total fat mass, 
kg Fat% N Age, yrs  BMI, kg/m²  Height, m  Weight, kg 
Total fat mass, 
kg  Total body fat%  
mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd)
AGES 1,019 49.7 (5.9) 25.6 (3.1) 1.78 (0.06) 81.3 (11.4) ‐ 22.0 (5.5) 1,356 52.0 (6.5) 24.9 (3.8) 1.64 (0.05) 67.1 (10.5) ‐ 34.0 (5.0)
Amish 406 50.7 (15.0) 26.5 (3.4) 1.72 (0.06) 78.2 (12.1) 15.9 (7.5) 19.7 (6.5) 444 52.2 (14.4) 28.4 (5.4) 1.60 (0.06) 72.4 (14.4) 25.8 (8.9) 35.4 (6.5)
CHS 349 77.6 (5.0) 26.5 (3.4) 1.73 (0.06) 79.4 (10.9) 23.1 (7.7) 29.4 (6.6) 572 (76.9 (4.3) 26.1 (4.4) 1.59 (0.06) 66.2 (12.1) 28.4 (9.6) 42.6 (7.5)
CoLaus 2,539 52.9 (10.8) 26.6 (4.2) 1.75 (0.07) 81.5 (13.4) ‐ 23.9 (6.0) 2,850 53.9 (10.7) 25.2 (4.9) 1.62 (0.07) 66.4 (13.0) ‐ 34.4 (8.2)
EPIC‐Obesity 1,121 63.2 (8.9) 28.4 (3.9) 1.74 (0.07) 85.9 (13.0) 19.9 (7.6) 26.4 (7.1) 1,422 62.2 (8.7) 28.5 (5.2) 1.61 (0.06) 74.1 (13.8) 28.4 (11.1) 43.8 (10.5)
ERF 900 48.8 (14.5) 27.2 (3.97) 1.75 (0.07) 82.8 (13.5) 22.0 (8.6) 26.9 (7.1) 1187 47.7 (14.5) 26.4 (4.8) 1.61 (0.07) 69.1 (13.1) 26.4 (9.7) 38.7 (7.6)
FamHS 388 59.9 (12.3) 29.6 (4.8) 1.76 (0.07) 91.8 (15.8) 30.7 (10.5) 27.9 (7.6) 421 64.6 (9.8) 28.7 (6.3) 1.60 (0.06) 74.4 (17.6) 33.6 (12.8) 38.7 (7.7)
Fenland 615 44.5 (7.4) 27.6 (3.9) 1.77 (0.07) 86.8 (13.9) 24.7 (8.6) 28.0 (6.7) 787 45.3 (7.2) 26.7 (5.5) 1.64 (0.06) 71.5 (15.3) 27.4 (10.7) 37.6 (7.7)
Framingham 1,003 64.1 (11.2) 26.7 (2.9) 1.73 (0.07) 80.1 (10.2) 22.8 (6.1) 28.2 (5.5) 1745 64.3 (11.4) 26.3 (4.3) 1.60 (0.07) 67.1 (11.6) 27.9 (8.8) 41.1 (7.3)
GOOD 940 18.9 (0.6) 22.4 (3.2) 1.82 (0.07) 73.9 (11.6) 13.2 (7.9) 17.1 (7.4) 0 ‐ ‐ ‐ ‐ ‐ ‐
KORAF3 773 62.5 (10.0) 28.2 (3.5) 1.73 (0.07) 84.9 (12.1) 24.3 (7.3) 28.1 (5.0) 787 61.6 (9.9) 27.9 (5.0) 1.61 (0.06) 71.9 (13.2) 28.1 (8.5) 38.4 (5.2)
KORAS4/F4 874 54.1 (8.9) 28.4 (4.2) 1.74 (0.07) 86.5 (14.1) 24.3 (7.6) 28.0 (4.9) 920 53.6 (8.8) 27.9 (5.3) 1.61 (0.06) 72.6 (13.7) 27.3 (8.6) 37.5 (5.4)
Lolipop ‐  Europeans 1,238 55.0 (9.7) 28.3 (4.7) 1.75 (0.07) 86.8 (15.7) 24.8 (11.3) 27.5 (7.8) 204 51.3 (10.4) 27.2 (5.7) 1.63 (0.06) 72.5 (15.5) 28.0 (10.9) 37.3 (7.0)
Lolipop ‐ Indian‐Asians 6,535 54.0 (10.9) 27.0 (4.1) 1.70 (0.07) 78.4 (13.4) 22.2 (9.3) 27.5 (7.3) 1,022 56.9 (10.0) 28.8 (5.3) 1.56 (0.06) 69.5 (12.7) 27.8 (9.1) 39.1 (6.4)
Rotterdam 1,043 63.9 (5.6) 25.9 (2.8) 1.76 (0.06) 80.5 (10.0) 23.4 (7.6) 28.9 (6.2) 1,395 64.2 (6.0) 26.3 (3.8) 1.63 (0.06) 70.2 (10.7) 28.4 (8.8) 29.0 (6.6)





























































































≥ 93% ≥ 97% > 0.05 SAS
BPPP iPLEX™  Sequenom MassARRAY® ≥ 99% NA >0.0001 PLINK
METSIM Custom TaqMan® SNP Genotyping Assays (Applied Biosystems, Warrington, UK) ≥ 95% ≥ 96% >0.05 SPSS
MrOS Sweden ‐ Hologic iPLEX™  Sequenom MassARRAY® ≥ 98% ≥ 97% > 0.45 SAS
MrOS Sweden ‐ Lunar iPLEX™  Sequenom MassARRAY® ≥ 98% ≥ 97% > 0.42 SAS
RISC Fluorescence‐based competitive allele‐specific PCR (Kbiosciences, Hoddesdon, UK) ≥ 98% ≥ 98% > 0.05 SAS








Short name Full name Call rate* Other exclusions
deCODE deCODE genetics sample set 38,446 ≥ 98% 1) missing phenotype
2) missing genotype




Fenland Fenland Study ‐ ≥ 95% 1) gender check
2) duplicates check
3) missing phenotype


















MRC Ely MRC Ely Study ‐ ≥ 95% 1) gender check
2) duplicates check
3) missing phenotype









































































MAF Call rate* p for HWE MAF Imputation quality*
deCODE Illumina HumanHap 300 370CNV BeadStudio ≥ 1% ≥ 96% > 10‐6 290,449 IMPUTE ≥ 1% proper‐info ≥ 0.40 14 SNPtest
Fenland Illumina MetaboChip GeneCall ‐ ≥ 90% > 10‐6 167,085 - - ‐ 14 Plink
Genmets Ilumina 610K Illuminus ≥ 1% ≥ 95% > 10‐6 555,388 MACH 1.0.10 ≥ 1% r2‐hat ≥ 0.83 14 Probabel
MRC Ely Illumina MetaboChip GeneCall ‐ ≥ 90% > 10‐6 149,302 - ‐ ‐ 14 Plink









> 10‐6 874,733 IMPUTE v2 - proper‐info ≥ 0.40 33 Merlin, PLINK
VIS Illumina Hap300v1 BeadStudio ≥ 2% ≥ 95% > 10‐6 308,996 MACH ≥ 1% r2‐hat ≥ 0.30 14 ProbABEL




















N Age, yrs BMI, kg/m² Height, m Weight, kg
Total fat mass, 
kg Fat% N Age, yrs  BMI, kg/m²  Height, m  Weight, kg 
Total fat mass, 
kg  Total body fat%  
mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd)
BPPP 927 48.4 (15.8) 26.8 (3.8) 1.77(0.07) 84.0 (13.1) 20.8 (6.7) 24.3 (6.7) 943 48.3 (15.5) 26.3 (4.7) 1.64 (0.06) 70.7 (12.8) 34.4 (7.5) 25.1 (9.4)
deCODE 533 62.5 (15.2) 27.1 (4.0) 1.76 (0.08) 83.9 (14.8) 23.9 (8.8) 26.6 (6.0) 2,014 56.9 (15.9) 25.8 (4.8) 1.64 (0.07) 69.9 (13.3) 27.2 (9.2) 37.0 (6.8) 
EPIC‐Norfolk 5,210 59.1 (9.0) 25.8 (2.7) 1.74 (0.06) 78.5 (9.7) 18.2 (6.2) 22.9 (5.7) 5,072 58.1 (8.9) 25.1 (3.3) 1.61 (0.06) 65.4 (9.4) 25.7 (8.4) 38.7 (8.3)
Fenland 1,465 46.9 (7.2) 27.0 (4.1) 1.78 (0.07) 85.4 (14.1) ‐ 23.7 (5.7) 1,667 46.9 (7.0) 26.5 (5.4) 1.64 (0.06) 71.1 (15.3) ‐ 35.7 (7.2)
GenMets cases 422 49.2 (10.4) 25.4 (3.1) 1.76 (0.06) 78.0 (10.4) 15.9 (5.7) 19.8 (5.0) 447 52.0 (11.6) 25.1 (4.1) 1.64 (0.06) 65.3 (10.4) 20.5 (7.8) 29.9 (6.7)
GenMets controls 425 49.2 (10.4) 29.4 (3.6) 1.78 (0.07) 91.2 (12.6) 23.9 (7.7) 25.3 (5.4) 432 52.4 (11.7) 29.7 (4.9) 1.64 (0.06) 76.6 (13.4) 28.9 (9.4) 36.1 (6.0)
METSIM 7,470 57.5 (7.0) 27.2 (4.1) 1.76 (0.06) 84.3 (13.9) 20.8 (8.0) 24.1 (6.5) ‐ ‐ ‐ ‐ ‐ ‐ ‐
MRC Ely 737 61.5 (9.1) 27.4 (4.0) 1.74 (0.07) 83.1 (13.3) 22.4 (7.0) 26.6 (5.2) 845 60.8 (9.2) 27.3 (5.4) 1.61 (0.06) 71.1 (14.4) 29.0 (10.2) 39.9 (6.5)
MrOS Sweden ‐ Hologic 917 75.2 (3.2) 25.9 (3.2) 1.76 (0.06) 80.2 (11.2) 18.5 (5.7) 22.7 (4.8) ‐ ‐ ‐ ‐ ‐ ‐ ‐
MrOS Sweden ‐ Lunar 1,946 75.5 (3.2) 26.5 (3.6) 1.74 (0.07) 80.7 (12.1) 23.7 (7.9) 28.7 (6.5) ‐ ‐ ‐ ‐ ‐ ‐ ‐
ORCADES 334 54.0 (15.6) 28.1 (4.1) 1.75 (0.06) 85.8 (13.0) 23.3 (8.6) 26.5 (6.8) 385 52.5 (15.7) 27.3 (5.3) 1.61 (0.06) 70.6 (13.8) 26.5 (10.2) 36.2 (7.3)
RISC 560 43.4 (8.6) 26.4 (3.5) 1.78 (0.07) 83.9 (12.6) 22.1 (6.6) 22.1 (6.6) 687 44.3 (8.1) 24.8 (4.4) 1.65 (0.06) 67.5 (12.4) 22.6 (9.2) 32.3 (7.7)
Twins UK 137 49.1 (12.8) 26.0 (3.1) 1.75 (0.06) 80.0 (10.0) ‐ 22.0 (6.0) 1,554 49.0 (12.9) 25.4 (4.6) 1.62 (0.06) 66.8 (12.5) ‐ 34.3 (7.5)
ULSAM 960 71.0 (0.6) 26.0 (3.2) 1.75 (0.06) 79.7 (10.8) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
VIS 315 55.7 (14.8) 27.5 (3.7) 1.76 (0.07) 85.5 (13.4) 31.7 (8.1) 37.2 (7.9) 466 56.4 (16.1) 27.2 (4.7) 1.62 (0.07) 71.3 (12.8) 26.1 (7.6) 36.7 (8.4)
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